ahlam1399
07-28-2016, 12:55 PM
AstraZeneca earnings hit by waning cholesterol drug sales
LONDON (Reuters) – Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter earnings down by nearly a third at drugmaker AstraZeneca, which is **w banking on new cancer medicines to revive its fortunes.http://feeds.feedburner.com/~ff/reuters/businessNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/businessNews?a=YLXebch**dU:HxbKL_pTloU:yIl2AUoC8zA ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=YLXebch**dU:HxbKL_pTloU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/businessNews?a=YLXebch**dU:HxbKL_pTloU:F7zBnMyn0Lo ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=YLXebch**dU:HxbKL_pTloU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/businessNews?a=YLXebch**dU:HxbKL_pTloU:V_sGLiPBpWU )
http://feeds.feedburner.com/~r/reuters/businessNews/~4/YLXebch**dU
LONDON (Reuters) – Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter earnings down by nearly a third at drugmaker AstraZeneca, which is **w banking on new cancer medicines to revive its fortunes.http://feeds.feedburner.com/~ff/reuters/businessNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/businessNews?a=YLXebch**dU:HxbKL_pTloU:yIl2AUoC8zA ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=YLXebch**dU:HxbKL_pTloU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/businessNews?a=YLXebch**dU:HxbKL_pTloU:F7zBnMyn0Lo ) http://feeds.feedburner.com/~ff/reuters/businessNews?i=YLXebch**dU:HxbKL_pTloU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/businessNews?a=YLXebch**dU:HxbKL_pTloU:V_sGLiPBpWU )
http://feeds.feedburner.com/~r/reuters/businessNews/~4/YLXebch**dU